Is the medicine right?
-
Gabriella Meloni [1]
-
[1] OECD
-
- Localización: European Law Journal, ISSN-e 1468-0386, Vol. 26, Nº. 1-2, 2020, págs. 104-107
- Idioma: inglés
- Enlaces
-
Resumen
Is asking the Better Regulation Agenda (BRA) to answer the same preconditions it requires for any regulatory action a proper treatment? Does any assessment of the agenda necessarily imply a thorough definition of the costs and the benefits deriving from its application or is it enough to provide a few key insights to perform it? Is the BRA really so ideological, deriving from “a liberal analytical framework that considers no regulation/state intervention” as the preferred option? Is regulatory quality an issue that “cannot realistically be solved”? Does the principle of subsidiarity as a policy objective need some revision? Several questions come to mind when reading a very thought‐provoking article that is very critical of the BRA but that in the end recognises some of its main qualities
